Close Menu

NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year.

The liquid biopsy firm reported total revenues of $21.7 million compared to $11.1 million in Q3 2017 and significantly above the $17.5 million Wall Street analysts, on average, had predicted.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.